Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In a takeover battle that lasted several months, drug maker Sanofi-Aventis emerged winner beating global rival GlaxoSmithKline among others to lap up a majority equity stake in India's Shantha Biotechnics from fellow French pharmaceutical firm Merieux Alliance. Shantha Biotechnics was valued at €550 million ($750 million) on expected sales of €90 million for the current financial year

You may also be interested in...



No Cease-Fire: India Seeks $190 Million Tax From Sanofi’s Shantha Deal

India’s tax department has filed a petition with the Supreme Court, challenging an earlier judgment that sided with Sanofi in a tax dispute that could impact future acquisitions in the country.

No Cease Fire: India Seeks $190 Million Tax From Sanofi’s Shantha Deal

India’s tax department has filed a petition with the Supreme Court, challenging an earlier judgment that sided with Sanofi in a tax dispute that could impact future acquisitions in the country.

Will The Vodafone Win Against India’s Income Tax Department Benefit Sanofi In Shantha Deal?

India Supreme Court ruling in Vodafone case may set precedent for offshore acquisitions, but Sanofi-Shantha deal has key differences.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC072314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel